Back to results
US 2024/0327804 A1Published application
Conjugates and methods of use thereof
AssigneeRegents of the University of Minnesota
InventorsCarston R. Wagner, Yiao Wang, Mark Distefano
Life of this patent
Estimating the term…
Abstract
Certain embodiments of the invention provide conjugates, chemically self-assembled nanoring (CSAN), and cell modified with CSAN as described herein. Certain embodiments of the invention provide a method for cell-based drug delivery. Certain embodiments of the invention provide a method of transferring a cargo from a sender cell to a receiver cell as described herein.
Claims20
A conjugate A1 comprising:
- A. a fusion protein comprising
- i. a targeting domain,
- ii. a first dihydrofolate reductase (DHFR) operably linked to a second DHFR, and
- iii. a prenyltransferase substrate domain;
- B. a linker A operably linked to the prenyltransferase substrate domain of the fusion protein;
- and
- C. a therapeutic agent or a detectable agent operably linked to linker A with a linker B;
- or
- a conjugate A1 comprising
- A. a fusion protein comprising
- i. a targeting domain,
- ii. a first dihydrofolate reductase (DHFR) operably linked to a second DHFR, and
- B. a therapeutic agent or a detectable agent operably linked to the DHFR (e.g., the second DHFR) with a linker B.
10 more elements
A chemically self-assembled nanoring (CSAN) comprising a plurality of conjugate B1 and fusion protein B2, and a plurality of bisMTX compounds,
- wherein conjugate B1 comprises:
- A. fusion protein comprising
- i. a first dihydrofolate reductase (DHFR) operably linked to a second DHFR, and
- ii. a prenyltransferase substrate domain;
- and
- B. a lipid operably linked to the prenyltransferase substrate domain of the fusion protein;
- wherein conjugate B1 lacks a targeting domain;
- and
- wherein fusion protein B2 comprises:
- i. a targeting domain, and
- ii. a first dihydrofolate reductase (DHFR) operably linked to a second DHFR.
8 more elements
Dependencies are inferred from the claim text.